Hanson & Doremus Investment Management Has $3.91 Million Position in Pfizer Inc. (NYSE:PFE)

Hanson & Doremus Investment Management raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 154,389 shares of the biopharmaceutical company's stock after acquiring an additional 15,268 shares during the period. Hanson & Doremus Investment Management's holdings in Pfizer were worth $3,912,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Rialto Wealth Management LLC bought a new position in Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PFE. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Performance

NYSE PFE traded down $0.14 on Monday, reaching $24.40. The stock had a trading volume of 35,078,445 shares, compared to its average volume of 41,184,590. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $138.71 billion, a P/E ratio of 17.30, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The firm has a fifty day moving average of $23.06 and a two-hundred day moving average of $24.95.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the firm earned $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.05%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.